×
Science / Biology

CARVYKTI

Published Mar 01 2022 at 2:12 PM GMT
FDA.gov

FDA.gov @fda.gov

Continue reading at fda.gov
Key
Points
  • For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Credit
Tags
Continue reading at fda.gov
Trending

Stats

  • Published Mar 1, 2022 2:12 PM GMT